Insmed (NASDAQ:INSM) Director Melvin Md Sharoky Sells 10,000 Shares

Insmed, Inc. (NASDAQ:INSM) Director Melvin Md Sharoky sold 10,000 shares of the business’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $129.50, for a total transaction of $1,295,000.00. Following the transaction, the director owned 274,516 shares in the company, valued at $35,549,822. This represents a 3.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Insmed Price Performance

Shares of NASDAQ INSM opened at $132.60 on Friday. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $132.64. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The company’s 50-day moving average is $106.82 and its 200 day moving average is $85.31. The stock has a market capitalization of $28.03 billion, a P/E ratio of -23.22 and a beta of 0.95.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company had revenue of $107.42 million for the quarter, compared to analysts’ expectations of $104.06 million. During the same quarter in the prior year, the firm earned ($1.94) EPS. Insmed’s quarterly revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of Insmed from $90.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, June 11th. Wells Fargo & Company upped their target price on shares of Insmed from $130.00 to $140.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 12th. Stifel Nicolaus increased their price objective on shares of Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. Morgan Stanley increased their price objective on shares of Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research report on Thursday. Finally, Citigroup upgraded shares of Insmed to a “buy” rating in a research report on Tuesday, June 10th. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $132.57.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. increased its stake in shares of Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 221 shares in the last quarter. Elequin Capital LP purchased a new stake in shares of Insmed in the fourth quarter worth $28,000. ORG Partners LLC increased its stake in shares of Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 196 shares in the last quarter. Hilltop National Bank purchased a new stake in shares of Insmed in the second quarter worth $28,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Insmed in the second quarter worth $33,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.